Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shanghai Impact Closes D1 Round for Synthetic Lethality Drugs

publication date: Mar 14, 2022

Impact Therapeutics, a Shanghai biopharma, closed a Series D1 funding of undisclosed size to develop its anti-oncology molecules. Impact's portfolio is based on a synthetic lethality technology that it uses to generate novel DNA damage response (DDR) candidates. Synthetic lethality occurs when a mutation in two genes causes cell death, but a mutation in either gene alone does not. In 2020, Impact formed a JV with Junshi Pharma for its lead candidate, a PARP inhibitor. Junshi invested $50 million In the JV for a 50% share. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China